ACRS Earnings

ACRS reported its earnings on 2026-02-25, showcasing a revenue of 0.00 against an estimate of 2.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.15 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ACRS's earnings announcement on 2026-02-25, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, ACRS's stock price tends to shift by an average of -3.13% in the 10 days leading up to earnings and -5.80% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ACRS’s annual revenue to reach 2.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 36.82% and EPS estimates Revise Upward by 37.8% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ACRS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 36.82%, while EPS estimates moved Revise Upward by 37.8% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ACRS's stock price typically moves by -3.13% in the 10 days before its earnings and -5.80% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 2.00M.

The earnings call summary and Q&A reveal multiple concerns: regulatory risks for ATI-2138, competitive pressures in the atopic dermatitis market, decreased cash reserves, and lack of clear guidance on study timelines. While there are potential synergies with ITK and JAK3 inhibitors, uncertainties in strategic direction and financial sustainability overshadow positive aspects. Without a market cap, the overall sentiment leans negative due to these uncertainties and lack of strong positive catalysts.